Published Articles & Presentations

The information in our publications and presentations should be considered accurate only as of the date of the publications or presentations. We disclaim any obligation to supplement or update the information in these publications and presentations.

To learn more about our innovative technology:

Publications Presentations

Acute Treatment of Migraine with INP104: Exploratory Efficacy from the Phase 3 Open-Label STOP 301 Study

Poster presented at the 2021 American Headache Society (AHS) Virtual Annual Scientific Meeting. Authors: Tim R. Smith, MD, Sheena K. Aurora, MD, Jasna Hocevar-Trnka, MD, Stephen B. Shrewsbury, MB ChB Introduction: Intravenous dihydroergotamine mesylate (DHE), although long used effectively to…

Nasal Safety of Chronic Intermittent Use of INP104: Results From the Phase 3 Open-Label STOP 301 Study

Poster presented at the 2021 American Headache Society (AHS) Virtual Annual Scientific Meeting. Authors: Greg Davis, MD, MPH, Adil Fatakia, MD, Seth Pransky, MD, Alison E. Heald, MD, Sheena K. Aurora, MD, Jasna Hocevar-Trnka, MD, Stephen B. Shrewsbury, MB ChB…

Reduced Nausea When Dihydroergotamine Mesylate Is Delivered by INP104

Poster presented at the 2021 American Headache Society (AHS) Virtual Annual Scientific Meeting. Authors: LaDonna Randle, Sheena K. Aurora, MD, Jasna Hocevar-Trnka, MD, Stephen B. Shrewsbury, MB ChB Introduction: Dihydroergotamine mesylate (DHE) is an effective acute treatment for episodic migraine;…

12 13 14